THE HYPOGLUCEMIC SULFONYLUREA DRUGS—AN INTERIM EVALUATION
Authors: DEWITT STETTEN
Journal: Annals of Internal Medicine (1957)

Editorial1 May 1957THE HYPOGLUCEMIC SULFONYLUREA DRUGS—AN INTERIM EVALUATIONDEWITT STETTEN JR., M.D., Ph.D.DEWITT STETTEN JR., M.D., Ph.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-46-5-1005 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptBecause of the prominence of the hyperglucemia and the glucosuria as manifestations of diabetes mellitus, great reliance has been placed upon the correction of these abnormalities in the assessment of possible insulin substitutes. When a new agent comes to light which causes a lowering in the blood glucose concentration in normal subjects and in many diabetic patients, when this agent is effective upon oral administration and when this drug appears to be devoid of all important toxic side-reactions, it is inevitable that it be explored as a possible therapeutic agent. Such a drug, according to the clinical consensus, is 1-butyl-3-p-tolylsulfonylurea...1 SoskinLevine SR: Carbohydrate metabolism, 2nd Ed., 1952, Univ. of Chicago Press, Chicago. Google Scholar2 JoslynRootWhiteMarbleBailey EPHFPACC: The treatment of diabetes mellitus, 1946, Lea & Febiger, Philadelphia, p. 349 et seq. Google Scholar3 Duncan GG: Clinical experiences with sulfonylureas in diabetes mellitus, Preprint of Conference on Effects of Sulfonylureas and Related Compounds in Experimental and Clinical Diabetes, The New York Academy of Sciences, Feb. 14-15, 1957, pp. 15-16. Google Scholar4 PurnellAraiPrattHladElrick RYECH: Some observations on the mode of action of orinase, Metabolism 5: 778, 1956. MedlineGoogle Scholar5 MillerDulin WLWE: Orinase, a new oral hypoglycemic compound, Science 123: 584, 1956. CrossrefMedlineGoogle Scholar6 MoorhouseKark JARM: Physiologic actions of orinase and their relationship to the types of diabetes in man, Metabolism 5: 847, 1956. MedlineGoogle Scholar7 DulinJohnston WERL: Studies concerning the role of the liver in the hypoglycemic response of animals to orinase, Preprint of Conference on Effects of Sulfonylureas and Related Compounds in Experimental and Clinical Diabetes, The New York Academy of Sciences, Feb. 14-15, 1957, pp. 12-13. Google Scholar8 ColwellColwellColwell ARJAAR: Intrapancreatic perfusion of antidiabetic sulfonylureas, Metabolism 5: 749, 1956. MedlineGoogle Scholar9 BerthetSutherlandMarman JEWMH: Observations on the action of certain sulfonylureas, Metabolism 5: 768, 1956. MedlineGoogle Scholar10 FajansLouisSeltzerJohnsonGittlerHennesWajchenbergAckermanConn SSLHHSRDRDARBLIPJW: Metabolic effects of arylsulfonylurea compounds in normal men and in diabetic subjects, Metabolism 5: 820, 1956. MedlineGoogle Scholar11 AchelisHardebeck JDK: Ueber eine neue blutzuckersenkende Substanz, Deutsche med. Wchnschr. 80: 1452, 1955. CrossrefMedlineGoogle Scholar12 Creutzfeldt W: Pancreasbefunde bei Diabetikern nach Behandlung mit D860, Deutsche med. Wchnschr. 81: 841, 1956. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited BySulfonylureas: Effects in Vivo and in VitroJESSE ROTH, M.D., THADDEUS E. PROUT, M.D., IRA D. GOLDFINE, M.D., SIDNEY M. WOLFE, M.D., JOSEPH MUENZER, B.S., LEONARD E. GRAUER, M.D., MELVIN L. MARCUS, M.D.A Method for Determining 1-Butyl-3-p-Tolylsulphonylurea (Tolbutamide) in Human Blood Serum. 1 May 1957Volume 46, Issue 5Page: 1005-1008KeywordsAttentionBloodDiabetes mellitusDrugsGlucoseInsulinOral administration Issue Published: 1 May 1957 PDF DownloadLoading ...